Visiongain Publishes US PRP and Stem Cell Alopecia Treatment Market Report 2021-2031

12 February 2021

Visiongain has published a new report on US PRP and Stem Cell Alopecia Treatment Market Report 2021-2031: Forecasts, by End User (Dermatology Clinics, Hospitals). PLUS Profiles of Leading Pharma Contract Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

U.S. PRP and Stem Cell Alopecia Treatment market was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx billion by 2031. Increase in the number of people suffering from alopecia and growing awareness and acceptance of novel treatment techniques are some of the factors driving demand for these procedures.

Alopecia is a condition that causes hair to fall out in small areas, which can be unnoticeable. These patches may connect, however, and then become visible. Thisdisorder develops when the immune system outbreaks the hair follicles, resulting in hair loss.

Stem cell and platelet-rich plasma (PRP) therapies are considered as regenerative or biomedicines. They are minimally invasive and hence reduce the need for surgery. These therapies help arouse, rebuild, and strengthen hair regrowth, instead of removing damaged tissue from the scalp. Increasing inclination for minimally intrusive procedures over surgeries is expected to boost the U.S. market for PRP and Stem Cell Alopecia Treatment.

Novel therapies for alopecia are preferred by dermatologists and patients over conventional drugs such as corticosteroids. Greater preference for these therapies arises from efficient and faster hair regrowth as compared to other corticosteroid treatments. Additionally, ease of administration of these novel therapies is expected to drive demand over the forecast period.

Market Drivers
The US is observing a huge growth in the number of people suffering from alopecia. This growth has in-turn boosted the demand for the growth in the PRP and Stem Cell treatment market for diagnostic patient suffering from alopecia in the US.

Segment Analysis
US PRP and Stem cell market is segmented on the basis of end user industry, the market has been further segmented into hospitals, dermatology clinics, and other centres. The dermatology clinic segment is expected to dominate the market during the forecast period.The growth in the clinic segment is growing owing to the specialized treatment and easy accessibility available at these clinics along-with the alternative of low cost treatment provided by these clinics in the US.

Most of the treatments in the U.S. are done by dermatologists in their privately owned establishment. For instance, according to the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS), dermatologists treat 84.8 % of total alopecia patients in the U.S. This is paving the way for the segment a significant boost over the forecast period.

Competitive Landscape
Some of the companies profiled in the report include; Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Anderson Center for Hair, Evolution Hair Loss Institute, Savola Aesthetic Dermatology Center, PLC, Virginia Surgical Center, Hair Transplant Institute of Miami, and Colorado Surgical Center& Hair Institute.

The U.S. market for PRP and Stem Cell Alopecia Treatment consists of a large number of clinicsand institutes offering innovative alopecia treatment options such as PRP and stem cell therapies. Clinics providing these therapies are present across the country, with the highest number of treatments being carried out in dermatology clinics.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021


Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021


Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021


Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021